株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

組織工学および再生医療:各種技術と世界市場

Tissue Engineering and Regeneration: Technologies and Global Markets

発行 BCC Research 商品コード 228043
出版日 ページ情報 英文 200 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.67円で換算しております。
Back to Top
組織工学および再生医療:各種技術と世界市場 Tissue Engineering and Regeneration: Technologies and Global Markets
出版日: 2019年05月28日 ページ情報: 英文 200 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の組織工学および再生医療の市場は予測期間中34.8%のCAGR (年間複合成長率) で推移し、2018年の247億ドルから、2023年には1099億ドルの規模に成長すると予測されています。

当レポートでは、世界の組織工学および再生医療の市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、関連法規制、臨床試験動向、技術区分・材料・用途・地域/主要国別の動向と市場規模の推移と予測、競合環境、特許動向、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

  • 組織工学産業の進歩と将来性
  • 組織再生のためのナノテクノロジー
  • 遺伝子治療:将来の組織工学
  • 幹細胞技術
  • 法規制環境
  • 幹細胞治療と臍帯血バンクの倫理的課題
  • 医療システムの組織工学市場の発展への影響
  • 再生医療におけるバイオプリンティング技術
  • ポーターのファイブフォース分析
  • 臨床試験
    • 米国
    • 欧州
    • アジア
  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会

第4章 市場分析・予測:技術区分別

  • 細胞治療
  • 組織血管新生
  • 細胞培養
  • 小分子・生物学的製剤
  • 組織工学
  • 遺伝子治療

第5章 市場分析・予測:材料別

  • 合成材料
    • 生分解性合成ポリマー
    • 足場材:医療用ポリ乳酸
    • 人工血管グラフト材料
    • ハイドロゲル技術
  • 生物由来材料
    • コラーゲン
    • 異種組織
    • 遺伝子組み換え材料

第6章 市場分析・予測:用途別

  • 心臓血管疾患
    • 末梢血管疾患
    • 冠動脈疾患
  • 皮膚科
  • 筋骨格系
  • 整形外科
  • 骨修復・置換
  • 軟骨・結合組織損傷

第7章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 競合環境

  • 承認
  • 合意・拡張・提携
  • 製品上市・特許申請/承認
  • M&A

第9章 特許分析

第10章 企業プロファイル

  • ARTERIOCYTE MEDICAL SYSTEMS INC. (ISTO BIOLOGICS)
  • ATHERSYS INC.
  • CERAPEDICS, INC.
  • CO.DON AG
  • COOK MEDICAL INC.
  • CRYOLIFE, INC.
  • CYTORI THERAPEUTICS, INC.
  • GENZYME CORP.
  • KINETIC CONCEPTS, INC.
  • MESOBLAST LTD.
  • NUO THERAPEUTICS, INC. (CYTOMEDIX, INC.)
  • OCATA THERAPEUTICS, INC. (アステラス製薬)
  • ORGANOGENESIS INC. (ADVANCED BIOHEALING)
  • ORTHOPEUTICS LP
  • U.S. STEM CELL, INC. (BIOHEART INC.)
  • VERICEL CORP. (AASTROM BIOSCIENCES INC.)
  • WRIGHT MEDICAL GROUP N.V.
図表

List of Tables

  • Summary Table: Global Market for Tissue Engineering and Regeneration, by Region, Through 2023
    • Table 1: U.S. and European Differences in Regulatory Approval
    • Table 2: Main Aspects of Healthcare Provisions in Different Countries
    • Table 3: Active U.S. Clinical Trials for Tissue Engineering and Regenerative Medicine, 2015-2019
    • Table 4: Active European Clinical Trials Being Conducted for Tissue Engineering and Regenerative Medicine, 2015-2019
    • Table 5: Active Asian Clinical Trials for Tissue Engineering and Regenerative Medicine, 2015-2019
    • Table 6: Number of Clinical Trials Registered for Various Diseases, 2011-2016
    • Table 7: Application of Stem Cells in Regenerative Medicine
    • Table 8: Global Market for Tissue Engineering and Regeneration, by Segment, Through 2023
    • Table 9: Global Market for Tissue Engineering and Regeneration, by Therapeutic Product, Through 2023
    • Table 10: Autologous vs. Allogenic Cells: Manufacturing Process
    • Table 11: Global Market for Cell Therapy, by Region, Through 2023
    • Table 12: Stem Cells, Advantages and Clinical Trials on Cardiovascular Disease Treatments
    • Table 13: Types of Urinary Bladder Scaffolds Proposed, 2011-2017
    • Table 14: Investments in Cell Culture Technology, 2017-2018
    • Table 15: Projects and Their Assessment Stages, 2017
    • Table 16: Global Market for Small Molecules and Biologics, by Region, Through 2023
    • Table 17: FDA New Molecular Entity Approval Attributes, 2017 and 2018
    • Table 18: Global Market for Tissue-Engineering, by Region, Through 2023
    • Table 19: Global Market for Gene Therapy, by Region, Through 2023
    • Table 20: Global Market for Tissue Engineering and Regeneration, by Therapeutic Material, Through 2023
    • Table 21: Global Market for Synthetic Materials, by Type, Through 2023
    • Table 22: Global Market for Synthetic Materials, by Region, Through 2023
    • Table 23: Biodegradable Polymer Classification
    • Table 24: Global Market for Biodegradable Synthetic Polymers, by Region, Through 2023
    • Table 25: Commercial Polymeric Scaffold Products
    • Table 26: Global Market for Scaffolds, by Region, Through 2023
    • Table 27: Tissue Engineered Vascular Graft Utilized in Human Studies, 2011-2017
    • Table 28: Global Market for Artificial Vascular Grafts, by Region, Through 2023
    • Table 29: Global Market for Hydrogel Technology, by Region, Through 2023
    • Table 30: Global Market for Biologically Derived Materials, by Type, Through 2023
    • Table 31: Global Market for Biologically Derived Materials, by Region, Through 2023
    • Table 32: Global Market for Biologically Derived Collagen, by Region, Through 2023
    • Table 33: Commercially Available Xenogeneic Acellular Graft
    • Table 34: Global Market for Biologically Derived Xenogenic Tissue, by Region, Through 2023
    • Table 35: Global Market for Genetically Engineered Materials, by Type, Through 2023
    • Table 36: Global Market for Genetically Engineered Materials, by Region, Through 2023
    • Table 37: Global Market for Deoxyribonucleic Acid Transfection Vectors, by Region, Through 2023
    • Table 38: Global Market for Genetically Manipulated Cells, by Region, Through 2023
    • Table 39: Global Market for 3D Polymer Technology, by Region, Through 2023
    • Table 40: List of Polymer Scaffolds Fabricated for Tissue Engineering Utilizing 3D Printing
    • Table 41: Global Market for Transgenics in Tissue Engineering, by Region, Through 2023
    • Table 42: Global Market for Fibroblasts, by Region, Through 2023
    • Table 43: Commercially Available Fibroblast Based Skin Substitute
    • Table 44: Global Market for Neural Stem Cells, by Region, Through 2023
    • Table 45: Global Market for Gene-Activated Matrix, by Region, Through 2023
    • Table 46: List of Biologics Approved, 2017
    • Table 47: Global Market for Small Molecules and Biologics, by Region, Through 2023
    • Table 48: Global Market for Tissue Engineering and Regeneration, by Application, Through 2023
    • Table 49: Global Market for Tissue-Engineering and Regeneration in Cardiovascular Applications, by Region, Through 2023
    • Table 50: Cell Therapies by Different Companies to Treat Cardiovascular Diseases
    • Table 51: Global Market for Tissue-Engineering and Regeneration in Oncology, by Region, Through 2023
    • Table 52: Global and U.S. Statistics for Skin Damage Medical Conditions, 2018
    • Table 53: Acellular Skin Tissue-Engineered Products in the Market
    • Table 54: Cellular Skin Tissue-Engineered Products in the Market
    • Table 55: Global Market for Tissue-Engineering and Regeneration in Dermatology Applications, by Region, Through 2023
    • Table 56: Global Market for Tissue-Engineering and Regeneration in Musculoskeletal Applications, by Region, Through 2023
    • Table 57: Orthopedic Diseases, by Region: Key Facts
    • Table 58: Regenerative Medicine Companies, by Size and Region, 2011
    • Table 59: Global Market for Tissue-Engineering and Regeneration, by Region, Through 2023
    • Table 60: North American Commercialized Tissue-Engineering Products
    • Table 61: North American Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
    • Table 62: Tissue Engineering Research Conducted according to Different Universities
    • Table 63: Tissue-Engineering Products Offered by Different Companies
    • Table 64: Funds Allocated for Research Activities in Budget, 2016
    • Table 65: Share of Increase of Spending on Biologics in Canada, 2011-2016
    • Table 66: Shares of Tissue-Engineering Firms in Selected European Countries, 2016
    • Table 67: European Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
    • Table 68: Number of Deaths across Germany on Gender Differentiation, by Cause of Death, 2017
    • Table 69: Companies That Target Different Tissue-Engineering Areas in Germany
    • Table 70: Different Causes of Death: U.K. Statistics, 2017
    • Table 71: Companies That Target Different Tissue Engineering Areas in the U.K.
    • Table 72: Companies That Target Different Tissue Engineering Areas in France
    • Table 73: European Stem Cell Policies, by Country
    • Table 74: European Companies Developing Products in Tissue Engineering and Regeneration for Central Nervous System Disorders and Injuries
    • Table 75: Asia-Pacific Market for Tissue Engineering and Regeneration, by Segment, Through 2023
    • Table 76: Rest of World Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
    • Table 77: Global Statistics for Central Nervous System Disorders and Injuries, 2015
    • Table 78: Key Competitive Strategies Used in the Tissue-Engineering Market, by Development Type, 2016-2019
    • Table 79: Regulatory Approvals in the Tissue-Engineering Market, by Company, 2016-2019
    • Table 80: Key Approvals in the Tissue-Engineering Market, 2016-2019
    • Table 81: Shares of Agreements, Expansions and Collaborations in the Tissue-Engineering Market, by Company, 2016-2019
    • Table 82: Key Agreements, Expansions and Collaborations in the Tissue-Engineering Market, 2016-2019
    • Table 83: Shares of Product Launches and Patent Applications/Patent Approvals in the Tissue-Engineering Market, by Company, 2016-2019
    • Table 84: Key Product Launches in the Tissue-Engineering Market, 2016-2019
    • Table 85: Shares of Mergers and Acquisitions in the Tissue-Engineering Market, by Company, 2016-2019
    • Table 86: Key Mergers and Acquisitions in the Tissue-Engineering Market, 2016-2019
    • Table 87: Japanese Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
    • Table 88: European Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
    • Table 89: U.S. Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
    • Table 90: Isto Biologics: Recent Developments
    • Table 91: Athersys Inc.: Financials, 2015-2017
    • Table 92: Athersys Inc.: Recent Developments
    • Table 93: Cerapedics, Inc.: Recent Developments
    • Table 94: Co.don AG: Recent Developments
    • Table 95: Cook Medical Inc.: Recent Developments
    • Table 96: CryoLife, Inc.: Financials, 2015-2017
    • Table 97: CryoLife, Inc.: Recent Developments
    • Table 98: Cytori Therapeutics, Inc.: Financials, 2013-2015
    • Table 99: Cytori Therapeutics, Inc.: Recent Developments
    • Table 100: Genzyme Corp.: Financials, 2013-2015
    • Table 101: Genzyme Corp.: Recent Developments
    • Table 102: Kinetic Concepts, Inc.: Recent Developments
    • Table 103: Mesoblast Ltd.: Financials, 2013-2015
    • Table 104: Mesoblast Ltd.: Recent Developments
    • Table 105: Nuo Therapeutics, Inc.: Financials, 2013-2015
    • Table 106: Astella Pharma, Inc.: Recent Developments
    • Table 107: Organogenesis Inc.: Recent Developments
    • Table 108: Orthopeutics LP: Recent Developments
    • Table 109: U.S. Stem Cell, Inc.: Financials, 2016-2018
    • Table 110: U.S. Stem Cell, Inc.: Recent Developments
    • Table 111: Vericel Corp.: Financials, 2016-2018
    • Table 112: Vericel Corp.: Recent Developments
    • Table 113: Wright Medical Group N.V.: Financials, 2016-2018
    • Table 114: Wright Medical Technology Inc.: Recent Developments

List of Figures

  • Summary Figure: Global Market for Tissue Engineering and Regeneration, by Region, 2018-2023
    • Figure 1: Tissue-Engineering Strategies
    • Figure 2: Nanotechnology and Tissue Regeneration
    • Figure 3: Porter's Five Forces Model for Tissue-Engineering and Regenerative Medicine Market
    • Figure 4: Number of Clinical Trials Registered for Various Diseases, 2011-2016
    • Figure 5: FDA Approvals of Biologics, 2016-2018
    • Figure 6: Shares of Global Diabetes Prevalence, by Region, 2017
    • Figure 7: T-Cell Therapy Technique
    • Figure 8: Global Number of Orthopedic Surgeries, 2012-2020
    • Figure 9: Regenerative Medicine Companies, by Size and Region, 2011
    • Figure 10: United States' NIH Stem Cell Research Spending, 2013-2018
    • Figure 11: Shares of Heart Disease Deaths in the U.S., by Disease Type, 2017
    • Figure 12: Healthcare Spending in Germany, by Source, 2015 and 2040 (est.)
    • Figure 13: Pathway for Dissemination of Regenerative Medicine
    • Figure 14: Shares of Key Competitive Strategies Used in the Tissue-Engineering Market, by Development Type, 2016-2019*
    • Figure 15: Shares of Regulatory Approvals in the Tissue-Engineering Market, by Company, 2016-2019
    • Figure 16: Shares of Agreements, Expansions and Collaborations in the Tissue-Engineering Market, by Company, 2016-2019
    • Figure 17: Shares of Product Launches and Patent Applications/Patent Approvals in the Tissue-Engineering Market, by Company, 2016-2019
    • Figure 18: Shares of Mergers and Acquisitions in the Tissue-Engineering Market, by Company, 2016-2019
目次
Product Code: HLC101D

Report Highlights:

The global market for tissue engineering and regeneration should grow from $24.7 billion in 2018 to $109.9 billion by 2023 with a compound annual growth rate (CAGR) of 34.8% from 2018 to 2023.

North American market for tissue engineering and regeneration should grow from $12.3 billion in 2018 to $53.7 billion by 2023 with a CAGR of 34.2% from 2018 to 2023.

Asia-Pacific market for tissue engineering and regeneration should grow from $2.8 billion in 2018 to $15.6 billion by 2023 with a CAGR of 41.3% from 2018 to 2023.

Report Scope:

This report covers all revenues earned by regeneration therapies. These therapies are extensively used to replace and regenerate the cells, genes and tissues in a patient's body. The report considers revenue generated by products and services in the regenerative medicine market. Services include tools, along with cell and gene bank charges, where the cells and tissues are stored and treated properly pre- and post-experimentation and treatment. The report also covers revenues earned by small molecules and biologics (drugs) that speed up the regeneration process. Other drug therapy revenues (e.g., painkillers, analgesics) that can be used along with regenerative therapy are not included in the report, as they do not contribute to cell or tissue regeneration. The report covers all existing applications of regenerative medicine therapy.

The global tissue engineering and regeneration market is primarily categorized by segment, material, application and region. The major segments are therapeutic products, tools, banks and services. Therapeutic products are further segmented into cell therapy, gene therapy, tissue engineering, and small molecules and biologics based on product type. Therapeutic products are also categorized into synthetic materials, biologically derived materials, genetically engineered materials, and small molecules and biologics based on material. The report includes key technologies involved in regenerative medicine therapy. The study analyzes clinical trials and patents in different regions. The report provides an in-depth analysis of key companies operating in the global tissue engineering and regeneration market.

By region, the market is segmented into North America, Europe, Asia-Pacific and ROW. Companies profiled in this report include Advanced Cell Technology, Arteriocyte, Athersys, Bioheart, BioMimetic Therapeutics, BioTissue Technologies, Cerapedics, Cook Biotech, CryoLife, Cytograft Tissue Engineering, Cytomedix, Cytori Therapeutics, Genzyme/Sanofi, Integra LifeSciences, International Stem Cell, LifeCell/Kinetic Concepts and Mesoblast.

Report Includes:

  • 59 data tables and 56 additional tables
  • An overview of the global market for tissue engineering and regeneration technologies within the industry
  • Analysis of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • A look at the future trends, products details, and therapies available in the field of tissue engineering
  • Evaluation of the competitive environments, including new and potential markets for novel therapies and treatments
  • Coverage of regulatory dynamics, pipeline analysis, patent analysis, and market drivers, restrains, and opportunities
  • Comprehensive company profiles of leading market players, including Ocata Therapeutics, Inc. (Astellas Pharma, Inc.), Co.don AG, Cook Medical Inc., Cytori Therapeutics, Inc., and Kinetic Concepts, Inc. (KCI)

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Intended Audience
  • Source of Information and Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market Overview

  • Progress and Promises for Tissue-Engineering Industry
    • Body Parts That Can be Replaced by Tissue Engineering
  • Nanotechnology for Tissue Regeneration
    • Effects of Nanotechnology on Stem Cell Behavior for Tissue Regeneration
    • Nanotechnology in Tissue Regeneration Applications
  • Gene Therapies: The Future of Tissue Engineering
    • Progress
    • Prospects
  • Stem Cell Technologies Boon to Tissue Engineering
  • Regulatory Environment
    • Country-Specific Regulations
    • Regulatory Differences
  • Ethical Issues of Stem Cell Therapies and Cord Blood Banking
    • The Principle of Proportionality That Balances Means and Objectives
  • Impact of Healthcare System on Tissue-Engineering Market Development
  • Bioprinting Technology in Regenerative Medicine
  • Porter's Five Forces Analysis of Tissue Engineering and Regeneration Market
    • Moderate Bargaining Power of Supplier
    • Low Bargaining Power of Buyer
    • Moderate to Low Level of Threats from Substitute Products
    • Low to Moderate Threat of New Entrants
  • Clinical Trials
    • U.S. Clinical Trials for Tissue Engineering and Regenerative Medicine
    • European Clinical Trials for Tissue Engineering and Regenerative Medicine
    • Asian Clinical Trials for Tissue Engineering and Regenerative Medicine
  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities in Stem Cell Applications

Chapter 4: Market Breakdown by Segment

  • Therapeutic Products
    • Cell Therapy
    • Tissue Vascularization
    • Cell Culturing
    • Small Molecules and Biologics
    • Tissue Engineering
    • Gene Therapy

Chapter 5: Market Breakdown by Material

  • Synthetic Materials
    • Biodegradable Synthetic Polymers
    • Scaffolds: Medical Poly Lactic Acid
    • Artificial Vascular Graft Materials
    • Hydrogel Technology
  • Biologically Derived Materials
    • Collagen
    • Xenogenic Tissue
    • Genetically Engineered Materials

Chapter 6: Market Breakdown by Application

  • Cardiovascular Disorders
    • Peripheral Vascular Disease Applications
    • Coronary Artery Disease
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Orthopedics
  • Bone Repair and Replacement
  • Cartilage and Connective Tissue Damage

Chapter 7: Market Breakdown by Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Other European Countries
  • Asia-Pacific
    • India
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • Rest of World
    • Cartilage and Bone Tissue-Engineering Products
    • Cardiovascular Disease Products
    • Central Nervous System-Related Injuries and Diseases

Chapter 8: Competitive Landscape

  • Approvals
  • Agreements, Expansions and Collaborations
  • Product Launches and Patent Applications/Patent Approvals
  • Mergers and Acquisitions

Chapter 9: Patent Analysis

  • Japanese Patent Analysis
  • European Patent Analysis
  • U.S. Patent Analysis

Chapter 10: Company Profiles

  • ARTERIOCYTE MEDICAL SYSTEMS INC. (ISTO BIOLOGICS)
  • ATHERSYS INC.
  • CERAPEDICS, INC.
  • CO.DON AG
  • COOK MEDICAL INC.
  • CRYOLIFE, INC.
  • CYTORI THERAPEUTICS, INC.
  • GENZYME CORP.
  • KINETIC CONCEPTS, INC.
  • MESOBLAST LTD.
  • NUO THERAPEUTICS, INC. (CYTOMEDIX, INC.)
  • OCATA THERAPEUTICS, INC. (ASTELLAS PHARMA, INC.)
  • ORGANOGENESIS INC. (ADVANCED BIOHEALING)
  • ORTHOPEUTICS LP
  • U.S. STEM CELL, INC. (BIOHEART INC.)
  • VERICEL CORP. (AASTROM BIOSCIENCES INC.)
  • WRIGHT MEDICAL GROUP N.V.
Back to Top